| Code | CSB-RA013481MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to ADEL-Y01, targeting MAPT (microtubule-associated protein tau). MAPT plays a critical role in stabilizing microtubules in neuronal axons and regulating microtubule dynamics essential for neuronal structure and function. Under pathological conditions, MAPT undergoes abnormal hyperphosphorylation and aggregation, forming neurofibrillary tangles that are hallmark features of Alzheimer's disease and other tauopathies including frontotemporal dementia, progressive supranuclear palsy, and chronic traumatic encephalopathy. These tau aggregates disrupt neuronal transport, impair synaptic function, and contribute to neurodegeneration.
ADEL-Y01 is a reference antibody used in neurodegenerative disease research to investigate tau protein biology and pathology. This biosimilar provides researchers with a reliable tool for studying MAPT expression, localization, and post-translational modifications in various experimental models. It supports investigations into tau-mediated neurotoxicity, protein aggregation mechanisms, and potential therapeutic interventions targeting pathological tau species. This antibody is valuable for advancing understanding of tauopathy pathogenesis and evaluating disease-modifying strategies.
There are currently no reviews for this product.